Merck Prepares To Test Drive Biosimilar Pathway In The U.S.
Since the passage of healthcare reform legislation, many in the industry have questioned the viability of the biosimilar pathway, but Merck is ready to put it to the test.
Since the passage of healthcare reform legislation, many in the industry have questioned the viability of the biosimilar pathway, but Merck is ready to put it to the test.